Qinlock (ripretinib) — CareFirst (Caremark)

Initial criteria

• Used as a single agent for subsequent treatment of metastatic or unresectable cutaneous melanoma with activating KIT mutations
• Member has disease progression, intolerance, and/or projected risk of progression with BRAF-targeted therapy

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months